Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

PURPOSE: Inhibition of ribonucleotide reductase reduces the availability of the endogenous pool of deoxycytidine and may increase cytarabine (AraC) cytotoxicity. We performed a phase I dose escalation trial of AraC combined with GTI-2040, a 20-mer antisense oligonucleotide shown in preclinical studi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Klisovic, Rebecca B., Blum, William, Wei, Xiaohui, Liu, Shujun, Liu, Zhongfa, Xie, Zhiliang, Vukosavljevic, Tamara, Kefauver, Cheryl, Huynh, LeNguyen, Pang, Jiuxia, Zwiebel, James A., Devine, Steven, Byrd, John C., Grever, Michael R., Chan, Kenneth, Marcucci, Guido
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993318/
https://ncbi.nlm.nih.gov/pubmed/18559610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0109
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki